Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society MeetingBusiness Wire • 12/03/21
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual MeetingBusiness Wire • 11/22/21
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/21
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial ResultsBusiness Wire • 11/09/21
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021Business Wire • 10/26/21
Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency DisorderBusiness Wire • 10/25/21
Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency DisorderBusiness Wire • 09/20/21
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency DisorderBusiness Wire • 08/26/21
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug DesignationBusiness Wire • 08/17/21
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial ResultsBusiness Wire • 08/10/21
Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021Business Wire • 08/03/21
Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With OrionBenzinga • 08/03/21
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of GanaxoloneBusiness Wire • 08/03/21
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline UpdateBusiness Wire • 08/03/21
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.Business Wire • 07/01/21